Fulgent Genetics Yönetim

Yönetim kriter kontrolleri 2/4

Fulgent Genetics CEO'su Ming Hsieh, May2016 tarihinde atandı, in görev süresi 8.5 yıldır. in toplam yıllık tazminatı $ 5.31M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.8% maaş ve 81.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 28.52% ine doğrudan sahiptir ve bu hisseler € 149.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 4.7 yıl ve 3.8 yıldır.

Anahtar bilgiler

Ming Hsieh

İcra Kurulu Başkanı

US$5.3m

Toplam tazminat

CEO maaş yüzdesi	18.8%
CEO görev süresi	8.5yrs
CEO sahipliği	28.5%
Yönetim ortalama görev süresi	4.7yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ming Hsieh'un ücretlendirmesi Fulgent Genetics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$165m
Jun 30 2024	n/a	n/a	-US$163m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$5m	US$1m	-US$168m
Sep 30 2023	n/a	n/a	-US$64m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$5m	US$948k	US$143m
Sep 30 2022	n/a	n/a	US$272m
Jun 30 2022	n/a	n/a	US$392m
Mar 31 2022	n/a	n/a	US$461m
Dec 31 2021	US$6m	US$664k	US$507m
Sep 30 2021	n/a	n/a	US$569m
Jun 30 2021	n/a	n/a	US$493m
Mar 31 2021	n/a	n/a	US$417m
Dec 31 2020	US$248k	US$240k	US$214m
Sep 30 2020	n/a	n/a	US$48m
Jun 30 2020	n/a	n/a	US$3m
Mar 31 2020	n/a	n/a	-US$459k
Dec 31 2019	US$240k	US$240k	-US$411k
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$240k	US$240k	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$240k	US$240k	-US$3m

Tazminat ve Piyasa: Ming 'nin toplam tazminatı ($USD 5.31M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.03M ).

Tazminat ve Kazançlar: Ming şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Ming Hsieh (68 yo)

8.5yrs

Görev süresi

US$5,309,167

Tazminat

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.52% € 149.7m
Jian Xie	COO & President	6.6yrs	US$1.79m	1.42% € 7.4m
Paul Kim	Chief Financial Officer	8.8yrs	US$1.78m	0.40% € 2.1m
Hanlin Gao	Chief Scientific Officer & Laboratory Director	8.2yrs	US$1.49m	2.8% € 14.7m
Natalie Prescott	General Counsel & Chief Privacy Officer	2.5yrs	Veri yok	Veri yok
Doreen Ng	VP of Operations & Compliance and GM of Houston Office	4.1yrs	Veri yok	Veri yok
Jakub Sram	Vice President of Business Development & Sales	9.8yrs	Veri yok	Veri yok
Ellen Tsui	Vice President of Human Resources	2.5yrs	Veri yok	Veri yok
Brandon Perthuis	Chief Commercial Officer	4.7yrs	Veri yok	Veri yok
Lawrence Weiss	Chief Medical Officer	3.5yrs	Veri yok	Veri yok
Ray Yin	President & Chief Scientific Officer of Fulgent Pharma	2yrs	Veri yok	Veri yok

4.7yrs

Ortalama Görev Süresi

58yo

Ortalama Yaş

Deneyimli Yönetim: 7F0 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 4.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.52% € 149.7m
Regina Groves	Independent Non-Employee Director	1.8yrs	US$625.60k	0.0039% € 20.4k
Linda Marsh	Independent Director	5.3yrs	US$270.50k	0.061% € 320.2k
Michael Nohaile	Independent Non-Employee Director	2.3yrs	US$268.50k	0.0078% € 40.9k

3.8yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 7F0 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

Fulgent Genetics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

COO & President recently sold €543k worth of stock

Chief Financial Officer recently sold €320k worth of stock

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Recent updates

Third quarter 2024 earnings released: US$0.48 loss per share (vs US$0.44 loss in 3Q 2023)

Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024

New minor risk - Shareholder dilution

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023)

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

COO & President recently sold €543k worth of stock

New minor risk - Share price stability

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold €320k worth of stock

Second quarter 2023 earnings released: US$0.38 loss per share (vs US$0.38 profit in 2Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Full year 2022 earnings released: EPS: US$4.77 (vs US$17.25 in FY 2021)

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Chief Financial Officer recently sold €62k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: US$0.057 (vs US$4.13 in 3Q 2021)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold €94k worth of stock

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

Chief Financial Officer recently sold €61k worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Investor sentiment deteriorated over the past week

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold €54k worth of stock

Chief Operating Officer recently sold €102k worth of stock

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS US$4.13 (vs US$2.11 in 3Q 2020)

Chief Operating Officer recently sold €99k worth of stock

Second quarter 2021 earnings released: EPS US$2.74 (vs US$0.15 in 2Q 2020)

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquired CSI Laboratories, Inc.

Investor sentiment improved over the past week